Sorbitol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sorbitol: From an Osmotic Agent and Excipient to Exercise-Induced Malignant Hyperthermia
One-Sentence Summary
Sorbitol is a sugar alcohol used in injectable form (osmotic and fluid-replacement use) and as a pharmaceutical excipient. The TxGNN model predicts it may be effective for exercise-induced malignant hyperthermia, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is a computational output only and has no clinical backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record |
| Predicted New Indication | Exercise-induced malignant hyperthermia |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Sorbitol is a sugar alcohol used as an osmotic agent and as a formulation excipient. Its pharmacology has no known link to the predicted disease.
Exercise-induced malignant hyperthermia is associated with dysregulated calcium handling in skeletal muscle (ryanodine receptor dysfunction). Sorbitol has no known action on this pathway. The high score (0.994) most likely reflects proximity in the knowledge graph rather than pharmacology, so the prediction should be treated as a likely knowledge-graph artefact.
Other top-ranked predictions were also reviewed. None has trial evidence, and only two have any indirect literature:
- Congestive heart failure: the literature shows only an association between raised myocardial sorbitol and diastolic dysfunction in diabetes. This suggests possible harm rather than benefit.
- Infectious otitis media: the only relevant paper is a trial of xylitol, a different sugar alcohol, which cannot be extrapolated to sorbitol.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for exercise-induced malignant hyperthermia.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05957P | OSMOFUNDIN INJECTION 20% (B Braun Medical Industries Sdn Bhd) | Injection | Not stated in the licence record |
Safety Considerations
- Contraindications (knowledge-graph signal, not label text): Active peptic ulcer disease is listed as a contraindication in the TxGNN knowledge graph.
- Drug Interactions (2 found):
- Tolevamer: Major
- Lamivudine: Moderate
Package insert warnings and contraindications were not available. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no clinical trials, no literature and no plausible mechanism. The evidence level is L5. Alternative predictions (heart failure, otitis media) have only indirect or unfavourable evidence. Sorbitol also carries a major interaction signal, and the package insert safety data have not been reviewed.
To proceed, the following is needed:
- Mechanism of action data for sorbitol, and any rationale linking it to calcium handling in skeletal muscle
- Package insert warnings and contraindications from the Singapore regulator
- Any preclinical or clinical evidence specific to sorbitol in the predicted disease
- Review of the Major interaction with tolevamer and the Moderate interaction with lamivudine
- Clarification of the approved indication for the registered product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.